Page 128 - Read Online

Shek et al. Cancer Drug Resist 2019;2:69-81 I http://dx.doi.org/10.20517/cdr.2018.20 Page 79

5. Hammers CM, Stanley JR. Antibody phage display: technique and applications. J Invest Dermatol 2014;134:1-5.
6. Kurosawa K, Lin W, Ohta K. Chimeric antibodies. Methods Mol Biol 2014;1060:139-48.
7. Liu JK. The history of monoclonal antibody development - progress, remaining challenges and future innovations. Ann Med Surg (Lond)
2014;3:113-6.
8. Scheen AJ. International classification of various types of monoclonal antibodies. Rev Med Liege 2009;64:244-7.
9. Goldenberg DM. Radiolabelled monoclonal antibodies in the treatment of metastatic cancer. Curr Oncol 2007;14:39-42.
10. Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology
2013;2:e26333.
11. Sallman DA, Macklin E, Ali S, Michaelson J, Barnes JA, et al. Rituximab hypersensitivity reactions (HSR): predictors of recurrent and
severe reactions based on severity of reaction, NHL histologic subtype, and burden of disease. J Clin Oncol 2012;30.
12. Weiss RB, Baker JR Jr. Hypersensitivity reactions from antineoplastic agents. Cancer Metastasis Rev 1987;6:413-32.
13. Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, et al. A high incidence of late-onset neutropenia following rituximab-containing
chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007;18:364-9.
14. Le Guenno G, Ruivard M, Charra L, Philippe P. Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura.
Intern Med J 2011;41:202-5.
15. Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, Lynch DM, Marquis K, et al. Hypersensitivity reactions to therapeutic
monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol 2018;142:159-70.e2.
16. International HapMap C. The international HapMap project. Nature 2003;426:789-96.
17. Lee NH. Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of
anticancer agents. Anticancer Agents Med Chem 2010;10:583-92.
18. Yan L, Beckman RA. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques
2005;39:565-8.
19. Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more
effective drug therapy. Philos Trans R Soc Lond B Biol Sci 2005;360:1563-70.
20. Yong WP, Innocenti F, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 2006;62:35-46.
21. Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol 2017;6:576-88.
22. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:633-59.
23. Qiu WQ, de Bruin D, Brownstein BH, Pearse R, Ravetch JV. Organization of the human and mouse low-affinity Fc gamma R genes:
duplication and recombination. Science 1990;248:732-5.
24. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for
therapeutic antibodies. Int Immunol 2001;13:1551-9.
25. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006;11:81-8.
26. Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug
Metab Pharmacokinet 2014;29:12-9.
27. Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 2014;1845:84-9.
28. Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers. Ann
Pharmacother 2000;34:161-4.
29. Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal
antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 1994;54:1517-28.
30. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet
2010;49:493-507.
31. Fellner C. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T
2012;37:503-30.
32. Berdeja J, Jagannath S, Zonder J, Badros A, Kaufman JL, et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide
and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study. Clin
Lymphoma Myeloma Leuk 2016;16:129-38.
33. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969;13:1-110.
34. Kamath AV. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discov Today Technol 2016;21-
22:75-83.
35. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998;76:231-48.
36. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical
efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.
37. Trotta AM, Ottaiano A, Romano C, Nasti G, Nappi A, et al. Prospective evaluation of cetuximab-mediated antibody-dependent cell
cytotoxicity in metastatic colorectal cancer patients predicts treatment efficacy. Cancer Immunol Res 2016;4:366-74.
38. Zhang W, Wang X, Li J, Duan MH, Zhou DB. Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese
diffuse large B-cell lymphoma. Chin Med J (Engl) 2010;123:198-202.
39. Sachs UJ, Socher I, Braeunlich CG, Kroll H, Bein G, et al. A variable number of tandem repeats polymorphism influences the
transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology 2006;119:83-9.
40. Billiet T, Dreesen E, Cleynen I, Wollants WJ, Ferrante M, et al. A genetic variation in the neonatal Fc-receptor affects anti-TNF drug
concentrations in inflammatory bowel disease. Am J Gastroenterol 2016;111:1438-45.